Royalty Pharma (STU:RPD) Net Interest Margin (Bank Only) %


STU:RPD Royalty Pharma PLC STU:RPD
72 GF Score
Price €49.69
GF Value €32.65
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:RPD
72GF Score
Royalty Pharma PLC STU:RPD
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Royalty Pharma (STU:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €49.69 is trading 52.2% above its estimated GF Value™ of €32.65. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for STU:RPD:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €32.65 vs. price of €49.69 (52.2% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the STU:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for STU:RPD

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€49.69
Price
€32.65
GF Value